Posts Archive

Phase II HOVON 143 Study Trial Update 63rd ASH Annual Meeting 80 Ixazomib, Daratumumab and Low Dose Dexamethasone in Intermediate-Fit...

(PRIME) NCT03288493: Phase 1/2 - P-BCMA-101 Tscm CAR-T Cells in the Treatment of Patients With Multiple Myeloma (MM) NCT03288493: Phase...

A Study to Evaluate Dara-CyBorD in Previously Untreated and Relapsed Subjects With Multiple Myeloma NCT02951819: Phase 2 - Evaluate...

Dendritic Cell/Myeloma Fusion Vaccine for Multiple Myeloma (BMT CTN 1401) Phase II Multicenter Trial of Single Autologous Hematopoietic...

The purpose of this study is to explore the combination of Elotuzumab in combination with autologous stem cell transplantation and...

NCT02786511: Longterm Follow-up of Subjects Treated With bb2121 NCT02786511: Longterm Follow-up of Subjects Treated With bb2121 This is a...

STORM Selinexor Treatment of Refractory Myeloma (STORM) This is a Phase 2b, single-arm, open-label, multicenter study of selinexor 80 mg...

Study of elotuzumab in combination with pomalidomide and low dose dexamethasone (EPd Cohort) and elotuzumab in combination with nivolumab...

NCT02546167: Phase 1 - CART-BCMA Cells for Multiple Myeloma Open-label, single-center, pilot study to assess the safety and feasibility...

Phase 3 A.R.R.O.W. trial - ARROW Kd The purpose of the study is to compare the progression-free survival (PFS) of once-weekly carfilzomib...

GEM14 Phase III GEM2014MAIN: Maintenance With Ixazomib + Len/Dex vs Len/Dex After VRd + ASCT in Newly Diagnosed MM Trial Studying...

An Open Label, Phase I, Dose Escalation Study to Characterize the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of...

DREAMM-1 study Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Clinical Activity...

NCT02046070: Phase 2 Study to Evaluate the Oral Combination of Ixazomib (MLN9708) With Cyclophosphamide and Dexamethasone in Patients...

NCT02045017: Phase 2: Efficacy and Safety of Pomalidomide and Dexamethasone in RRMM Patients With Renal Insufficiency Efficacy and Safety...

NCT02215967: Phase 1 - Study of T Cells Targeting B-Cell Maturation Antigen for Previously Treated Multiple Myeloma Background: - T cells...

STaMINA Trial follow up Continued, Long-Term Follow-Up and Lenalidomide Maintenance Therapy for Patients on BMT CTN 0702 Protocol (BMT...

NCT02252263: Phase 1: A Phase I Open Label Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination...

NCT01794520: Phase 1/2: Study Evaluating ABT-199 in Participants With Relapsed or Refractory Multiple Myeloma The phase 1 primary...